TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Mabpharm Limited ( (HK:2181) ).
Mabpharm Limited has announced its upcoming Annual General Meeting (AGM) scheduled for June 18, 2025, in Shanghai. Key agenda items include the consideration of the company’s audited financial statements for 2024, re-election of several directors, re-appointment of Ernst & Young as auditors, and a proposal to authorize the company to repurchase up to 10% of its issued shares. This announcement reflects the company’s ongoing governance and strategic financial management, potentially impacting shareholder value and market confidence.
More about Mabpharm Limited
Mabpharm Limited is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative drugs in the field of oncology and autoimmune diseases.
YTD Price Performance: 76.79%
Average Trading Volume: 717,190
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.04B
Find detailed analytics on 2181 stock on TipRanks’ Stock Analysis page.